Publication: First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.
No Thumbnail Available
Identifiers
Date
2017-10-10
Authors
Fernández-de-Misa, R
Hernández-Machín, B
Servitje, O
Valentí-Medina, F
Maroñas-Jiménez, L
Ortiz-Romero, P L
Sánchez Schmidt, J
Pujol, R M
Gallardo, F
Pau-Charles, I
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. To assess the daily clinical practice approach to LyP and the response to first-line treatments. This was a retrospective study enrolling 252 patients with LyP. Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse.
Description
MeSH Terms
Administration, Topical
Adolescent
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Lymphomatoid Papulosis
Male
Methotrexate
Middle Aged
Mycosis Fungoides
Neoplasms, Multiple Primary
Phototherapy
Receptors, Antigen, T-Cell
Retrospective Studies
Skin Neoplasms
Steroids
Young Adult
Adolescent
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Lymphomatoid Papulosis
Male
Methotrexate
Middle Aged
Mycosis Fungoides
Neoplasms, Multiple Primary
Phototherapy
Receptors, Antigen, T-Cell
Retrospective Studies
Skin Neoplasms
Steroids
Young Adult